MAA868

Novartis, Blackstone launch Anthos Therapeutics to develop cardiovascular drugs

Blackstone is investing $250 million, while Novartis is licensing MAA868, a drug for patients who are underserved by existing anti-coagulant drugs.

By Alaric DeArment

From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS

What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.

By Anna Keith, Vice President of LTSS Product & Strategy at Centene Corporation, and Phyllis Wojtusik, RN, Executive Vice President of Value-Based Care at Real Time Medical Systems

Closing the Quality-Affordability Gap in Workplace Mental Health

In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.

By Stephanie Baum

The Healthcare Payments Industry Faces a Perception Challenge

Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.

By Lisa Brooks, Vice President, Healthcare Partnerships